Biologic agents that target interleukin-5, interleukin-5 receptor and interleukin-4/interleukin-13 receptor in patients with COPD and elevated blood eosinophil counts reduce exacerbations (Figure 1) (21, 22). The gene discussed is IL5; the disease is chronic obstructive pulmonary disease.